Efficacy and safety of iGlarLixi versus IDegAsp by baseline β‐cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli‐D study

Documenti analoghi

• The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
  di: Ming Liu, et al.
  Pubblicazione: (2024)
• Evaluation of efficacy of iGlarLixi versus IDegAsp using derived time‐in‐ranges in Chinese adults with Type 2 diabetes: A post hoc analysis of the Soli‐D study
  di: Juan Liu, et al.
  Pubblicazione: (2025)
• Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli‐ SWITCH study
  di: Martin Haluzík, et al.
  Pubblicazione: (2025)
• Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN trials
  di: Wenying Yang, et al.
  Pubblicazione: (2024)
• Long‐term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli‐durability 24‐month observational study
  di: Rayaz A. Malik, et al.
  Pubblicazione: (2025)